B. Metzler seel. Sohn & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.3M Buy
67,805
+3,675
+6% +$122K 0.02% 395
2026
Q1
$1.93M Sell
64,130
-256
-0.4% -$8.24K 0.02% 394
2025
Q4
$2.01M Sell
64,386
-11,858
-16% -$292K 0.02% 404
2025
Q3
$1.54M Hold
76,244
0.01% 456
2025
Q2
$1.28M Hold
76,244
0.01% 481
2025
Q1
$1.17M Hold
76,244
0.01% 483
2024
Q4
$1.68M Buy
76,244
+50,995
+202% +$928K 0.02% 412
2024
Q3
$455K Hold
25,249
﹤0.01% 656
2024
Q2
$410K Buy
25,249
+1,087
+4% +$16.7K ﹤0.01% 655
2024
Q1
$341K Hold
24,162
﹤0.01% 667
2023
Q4
$252K Sell
24,162
-50,237
-68% -$469K ﹤0.01% 710
2023
Q3
$759K Buy
74,399
+50,237
+208% +$468K 0.01% 519
2023
Q2
$182K Hold
24,162
﹤0.01% 726
2023
Q1
$214K Hold
24,162
﹤0.01% 698
2022
Q4
$220K Hold
24,162
﹤0.01% 686
2022
Q3
$195K Hold
24,162
﹤0.01% 712
2022
Q2
$182K Hold
24,162
﹤0.01% 708
2022
Q1
$227K Hold
24,162
﹤0.01% 740
2021
Q4
$191K Buy
24,162
+9,246
+62% +$83.5K ﹤0.01% 705
2021
Q3
$145K Hold
14,916
﹤0.01% 695
2021
Q2
$148K Buy
+14,916
New +$158K ﹤0.01% 678

Other funds holding TEVA

B. Metzler seel. Sohn & Co's TEVA Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co increased its Teva Pharmaceuticals (TEVA) stake by 5.7% in Q2 2026, buying an estimated $122K and bringing the position to 67,805 shares worth $2.3M. The position accounts for 0.02% of the portfolio, ranked #395.

B. Metzler seel. Sohn & Co first reported a position in TEVA in Q2 2021 and has held it in 21 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • B. Metzler seel. Sohn & Co held 67,805 shares of Teva Pharmaceuticals worth $2.3M as of Q2 2026.
  • B. Metzler seel. Sohn & Co bought 3,675 Teva Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • Teva Pharmaceuticals made up 0.02% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #395 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Teva Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.